Functionally Immortalized

Alveolar Epithelial Cells

Studying the absorption and toxicity of inhaled drugs or chemicals requires a model reflecting the essential features of the air-blood barrier. For this purpose, InSCREENeX developed a novel alveolar type I cell line using the CI-SCREEN technology (recently published in Nature Communications; Lipps et al., 2018). In a joint collaboration project between the groups from Prof. Dr. Claus-Michael Lehr (Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Prof. Dr. Dagmar Wirth (Helmholtz Centre for Infection Research (HZI) and InSCREENeX the CI-hAELVi cell line was established and extensively characterized. This work is highlighted in the peer-reviewed paper published by Kuehn et al., 2016.

Specifications of CI-hAELVi

  • Characteristic expression of epithelial cell markers (e.g. Occludin, ZO-1)
  • Type-I-like properties (expression of Caveolin-1, absence of surfactant Prot C)
  • Growth in liquid-liquid as well as air-liquid conditions
  • Tight intercellular junctions and formation of desmosomes
  • Low permeability
  • Transepithelial Electrical Resistance (TEER)-formation
Product NameCat. No.InformationPrice
Human Alveolar Epithelial cells
INS-CI-1015Instruction ManualGet prices

Related Products

Product NameCat. No.SizePrice
huAEC Medium (ready-to-use)INS-ME-1013-100ml100 ml€ 82.00
huAEC Medium (ready-to-use)INS-ME-1013-500ml500 ml€ 315.00
huAEC Coating solutionINS-SU-1018-20ml20 ml€ 49.00
huAEC Coating solution INS-SU-1018-100ml100 ml€ 185.00
Freezing mediumINS-SU-100430 ml€ 39.00

Related Protocols for Cultivation of CI-hAELVi


  • Co-culture of human alveolar epithelial (hAELVi) and macrophage (THP-1) cell lines. Kletting S et al., ALTEX. 2017;34(4). doi: 10.14573/altex.1607191. Epub 2017 Nov 23 [link].
  • Human Alveolar Epithelial Cells Expressing Tight Junctions to Model the Air-Blood Barrier. Kuehn A et al., ALTEX. 2016; 33(3):251-60 [link].
  • In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells. Blondonnet R et al., JoVE 140 (2018): e58554 [link].
  • Capturing the Onset of Bacterial Pulmonary Infection in Acini‐On‐Chips. Artzy‐Schnirman A et al., Advanced Biosystems 2019;3(9). doi: 10.1002/adbi.201900026. [link].
  • Supramolecular Toxin Complexes for Targeted Pharmacological Modulation of Polymorphonuclear Leukocyte Functions. Heck AJ et al., Advanced healthcare materials. 8.17 (2019). doi: 10.1002/adhm.201900665. [link].
  • Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin. Ho DK et al., Mol Pharm 15 (3). doi: 10.1021/acs.molpharmaceut.7b00967. (2018) [link].
  • Nanoparticle induced barrier function assessment at liquid–liquid and air–liquid interface in novel human lung epithelia cell lines. Leibrock L et al., Toxicol. Res., 2019, 8, 1016-1027. doi: 10.1039/C9TX00179D. (2019) [link].
  • Azithromycin has lung barrier protective effects in a cell model mimicking ventilator-induced lung injury. Joelsson JP et al. ALTEX. 2020; doi:10.14573/altex.2001271 [link].
  • Biological effects of allergen-nanoparticle conjugates: uptake and immune effects determined on hAELVi cells under submerged vs. air-liquid interface conditions. Mills-Goodlet, R et al. Environmental Science: Nano (2020); doi:10.1039/C9EN01353A [link].
  • Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. Thanki, K et al. Journal of Controlled Release 310 (2019): 82-93. [link].
  • Mechanical stretch activates piezo1 in caveolae of alveolar type I cells to trigger ATP release and paracrine stimulation of surfactant secretion from alveolar type II cells. Diem, K et al. The FASEB Journal 34.9 (2020): 12785-12804. [link].

Stay in touch